4DMedical Ltd (ASX: 4DX) Share Price and News

Mr Livingston was previously one of the founding partners of Lake Imaging, subsequently becoming part of Integral Diagnostics Ltd,where John was Chief Executive Officer and Managing Director. He has commercial experience, having worked with the team at Lake Imaging and later Integral Diagnostics through acquisitions and the establishment of Greenfield facilities across Australia. During his career at Integral Diagnostics, John led the group through private equity investment with Advent Partners in 2014, and in 2015 John worked with Advent to list Integral Diagnostics on the ASX.

Dr Figlin established and directs the Kidney Cancer Program at Cedars-Sinai Medical Center, which aims to understand the biology of kidney cancer and translate that knowledge into novel treatment approaches. His leadership is in novel anticancer drugs that avoid the toxicity associated with standard treatments and furthers Cedars-Sinai's tradition of patient care. He is the Chair of the Medical Advisory Committee.

Dr Fouras is involved to translate cutting-edge respiratory imaging research into accessible clinical tools that address real-world challenges. Before founding 4DMedical, Dr Fouras was a Professor and Director of the Laboratory for Dynamic Imaging at Monash University, where his research in imaging fluid dynamics laid the foundation for XV Technology.

Mr Sutton is actively involved in Australia's start-up industry. He is interim CEO of AlleSense, a nanofabricated biosensor spinout from La Trobe University.

Dr McGinty an internationally expert in healthcare strategy and imaging economics, and advocate for patient-centred care. He has knowledge of reimbursement and negotiates strategic and contractual issues at the intersection of technology and healthcare. She is the member of the Medical Advisory Committee.

Professor Jenkins has career spanning four decades combined clinical practice, research, education and policy leadership at the levels of the profession. She served as a staff in respiratory medicine at Concord Hospital for 40 years, has led more than 34 clinical trials as principal investigator and authored more than 320 publications. Her work has focused on improving diagnostic pathways and outcomes for patients with respiratory disease, those presenting with breathlessness, COPD and asthma. She currently leads a Medical Research Future Fund trial developing a digital tool to assist general practitioners in assessing and managing patients with breathlessness. Professor Jenkins has held leadership positions in Australian respiratory medicine, including Chair of Lung Foundation Australia, the Thoracic Society of Australia and New Zealand and the National Asthma Council. She has also played a central role in shaping national respiratory health policy, clinical standards and patient advocacy initiatives.

-

-

-